

Karin Haustermans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7355165/publications.pdf>

Version: 2024-02-01

268
papers

16,261
citations

20817

60
h-index

18647

119
g-index

274
all docs

274
docs citations

274
times ranked

17009
citing authors

#	ARTICLE	IF	CITATIONS
1	Using ePROMs for follow-up after palliative radiotherapy: An exploratory study with patients and health care providers. Patient Education and Counseling, 2022, 105, 2355-2361.	2.2	4
2	Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2022, 167, 127-132.	0.6	20
3	Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and Oncology, 2022, 167, 7-13.	0.6	23
4	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.6	7
5	Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. European Urology, 2022, 82, 252-257.	1.9	32
6	Reply to Kamal Kant Sahu’s Letter to the Editor re: Veerle H. Groen, Karin Hausermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012 . European Urology, 2022, , .	1.9	0
7	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group. Clinical and Translational Radiation Oncology, 2022, 34, 1-6.	1.7	2
8	Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. European Journal of Cancer, 2022, 166, 254-269.	2.8	40
9	Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres. Radiotherapy and Oncology, 2022, 172, 32-41.	0.6	2
10	“Who needs a mean dose if you can FLAME?” Radiotherapy and Oncology, 2022, , .	0.6	0
11	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1211-1218.	6.4	23
12	Dosimetric impact of intrafraction prostate rotation and accuracy of gating, multi-leaf collimator tracking and couch tracking to manage rotation: An end-to-end validation using volumetric film measurements. Radiotherapy and Oncology, 2021, 156, 10-18.	0.6	5
13	Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiotherapy and Oncology, 2021, 156, 102-112.	0.6	19
14	The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment. Clinical and Translational Radiation Oncology, 2021, 26, 8-14.	1.7	2
15	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiotherapy and Oncology, 2021, 154, 60-69.	0.6	36
16	Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. European Urology Oncology, 2021, 4, 305-309.	5.4	40
17	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 2021, 39, 17-29.	1.6	58
18	Response to Schuler et al. patient-reported outcome measures (PROMs) in palliative radiotherapy. Radiotherapy and Oncology, 2021, 154, e12.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Radiation oncology in the new virtual and digital era. <i>Radiotherapy and Oncology</i> , 2021, 154, A1-A4.	0.6	8
20	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 787-796.	1.6	267
21	Deep learning dose prediction for IMRT of esophageal cancer: The effect of data quality and quantity on model performance. <i>Physica Medica</i> , 2021, 83, 52-63.	0.7	29
22	A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1121-1125.	0.8	1
23	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 41.	2.5	12
24	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. <i>Practical Radiation Oncology</i> , 2021, 11, 202-211.	2.1	13
25	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
26	Automated treatment planning of prostate stereotactic body radiotherapy with focal boosting on a fast-rotating O-ring linac: Plan quality comparison with C-arm linacs. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 59-72.	1.9	5
27	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
28	Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 98-104.	0.6	8
29	ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies. <i>Radiotherapy and Oncology</i> , 2021, 164, 92-97.	0.6	4
30	Reply to I. R. Vogelius et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 3086-3087.	1.6	5
31	Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics. <i>Radiotherapy and Oncology</i> , 2020, 142, 246-252.	0.6	61
32	Histopathological Features of MRI-Invisible Regions of Prostate Cancer Lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1235-1246.	3.4	24
33	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
34	Inflammation-Based Index and ⁶⁸ Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰ Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1014-1020.	5.0	28
35	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	2.8	16
36	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15

#	ARTICLE	IF	CITATIONS
37	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. <i>Acta Oncologica</i> , 2020, 59, 904-910.	1.8	1
38	A study to investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 50-53.	2.9	3
39	Image guidance in radiation therapy for better cure of cancer. <i>Molecular Oncology</i> , 2020, 14, 1470-1491.	4.6	63
40	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 246.	2.8	11
41	Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1055-1062.	0.8	14
42	Could Autoimmune Disease Contribute to the Abscopal Effect in Metastatic Hepatocellular Carcinoma?. <i>Hepatology</i> , 2020, 72, 1152-1154.	7.3	6
43	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	10.7	56
44	The use of patient reported outcome measures (PROMs) in palliative radiotherapy: A topical review. <i>Radiotherapy and Oncology</i> , 2020, 149, 94-103.	0.6	11
45	Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 147, 92-98.	0.6	109
46	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 194-200.	0.6	43
47	International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 148, 213-215.	0.6	65
48	Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection. <i>Journal of Urology</i> , 2020, 203, 713-718.	0.4	10
49	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. <i>BMC Cancer</i> , 2020, 20, 457.	2.6	7
50	Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. <i>Future Oncology</i> , 2020, 16, 2035-2044.	2.4	2
51	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecanermedicalscience</i> , 2020, 14, 1036.	1.1	5
52	Validation and IMRT/VMAT delivery quality of a preconfigured fast-rotating ring linac system. <i>Medical Physics</i> , 2019, 46, 328-339.	3.0	36
53	Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5-T magnetic resonance imaging guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 16-20.	2.9	10
54	Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. <i>Radiotherapy and Oncology</i> , 2019, 140, 131-142.	0.6	24

#	ARTICLE	IF	CITATIONS
55	NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 33-40.	0.6	28
56	Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. <i>Acta Oncologica</i> , 2019, 58, 1358-1365.	1.8	11
57	Pooled Analysis of external-beam Radiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). <i>European Journal of Cancer</i> , 2019, 121, 130-143.	2.8	9
58	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , 2019, 124, 35-39.	2.5	4
59	Improved repeatability of dynamic contrast-enhanced MRI using the complex MRI signal to derive arterial input functions: a test-retest study in prostate cancer patients. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3358-3369.	3.0	10
60	Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. <i>World Journal of Surgical Oncology</i> , 2019, 17, 89.	1.9	21
61	The Combination of Particle Irradiation With the Hedgehog Inhibitor GANT61 Differently Modulates the Radiosensitivity and Migration of Cancer Cells Compared to X-Ray Irradiation. <i>Frontiers in Oncology</i> , 2019, 9, 391.	2.8	18
62	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. <i>Urology</i> , 2019, 130, 113-119.	1.0	19
63	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
64	Reply to Laprie A. et al. <i>Radiotherapy and Oncology</i> , 2019, 130, 194.	0.6	0
65	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 44-60.	1.9	48
66	Feasibility of CT-Only 3D Dose Prediction for VMAT Prostate Plans Using Deep Learning. <i>Lecture Notes in Computer Science</i> , 2019, , 10-17.	1.3	2
67	Targeting the Hedgehog pathway in combination with X-ray or carbon ion radiation decreases migration of MCF7 breast cancer cells. <i>International Journal of Oncology</i> , 2019, 55, 1339-1348.	3.3	7
68	Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. <i>Medical Physics</i> , 2018, 45, 2205-2217.	3.0	15
69	Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 437-442.	0.6	21
70	Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 74-80.	0.6	101
71	Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients. <i>American Journal of Pathology</i> , 2018, 188, 795-804.	3.8	10
72	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 179-193.	4.4	57

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer, 2018, 18, 354.	2.6	16
74	Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac. Radiotherapy and Oncology, 2018, 128, 479-484.	0.6	49
75	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	1.9	13
76	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. European Urology Focus, 2018, 4, 369-375.	3.1	17
77	Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization. Radiotherapy and Oncology, 2018, 128, 161-166.	0.6	18
78	Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation. Cancer Research, 2018, 78, 659-670.	0.9	107
79	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
80	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	1.9	60
81	PET imaging in adaptive radiotherapy of gastrointestinal tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 385-403.	0.7	8
82	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Cancer Cell, 2018, 34, 1012-1026.e3.	16.8	209
83	Clinical Implementation of DeepVoxNet for Auto-Delineation of Organs at Risk in Head and Neck Cancer Patients in Radiotherapy. Lecture Notes in Computer Science, 2018, , 223-232.	1.3	9
84	Prospective data registration and clinical trials for particle therapy in Europe. Radiotherapy and Oncology, 2018, 128, 9-13.	0.6	20
85	Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial. Radiotherapy and Oncology, 2018, 128, 321-326.	0.6	36
86	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. Journal of Clinical Oncology, 2018, 36, 3500-3500.	1.6	25
87	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Research Protocols, 2018, 7, e11256.	1.0	12
88	Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?. Critical Reviews in Oncology/Hematology, 2017, 114, 43-52.	4.4	30
89	Modeling the dose dependence of the vis-absorption spectrum of EBT3 GafChromicâ„¢ films. Medical Physics, 2017, 44, 2532-2543.	3.0	19
90	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 2017, 24, 2252-2258.	1.5	186

#	ARTICLE	IF	CITATIONS
91	Multicenter validation of prostate tumor localization using multiparametric <scp>MRI</scp> and prior knowledge. Medical Physics, 2017, 44, 949-961.	3.0	23
92	The TRENDY multi-center randomized trial on hepatocellular carcinoma – Trial QA including automated treatment planning and benchmark-case results. Radiotherapy and Oncology, 2017, 125, 507-513.	0.6	20
93	Moderate dose escalation with volumetric modulated arc therapy improves outcome in rectal cancer. Acta Oncol ³ gica, 2017, 56, 1501-1506.	1.8	11
94	PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
95	PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
96	PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	1
97	Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer. Radiotherapy and Oncology, 2017, 124, 104-109.	0.6	37
98	Hepatic radiation injury mimicking metastasis in distal esophageal cancer. Acta Chirurgica Belgica, 2017, 117, 250-255.	0.4	2
99	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	1.9	77
100	The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 399.	4.1	27
101	Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer. BMC Cancer, 2017, 17, 634.	2.6	7
102	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	1.4	19
103	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget, 2016, 7, 24326-24338.	1.8	33
104	Towards 3D printed multifunctional immobilization for proton therapy: Initial materials characterization. Medical Physics, 2016, 43, 5392-5402.	3.0	15
105	Potential benefits of dosimetric VMAT tracking verified with 3D film measurements. Medical Physics, 2016, 43, 2162-2173.	3.0	4
106	MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
107	MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3N0 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
108	MP69-06 THE ROLE OF EXTENDED OR SUPER-EXTENDED LYMPH NODE DISSECTION FOR STAGING OF HIGH-RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0

#	ARTICLE	IF	CITATIONS
109	MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS. Journal of Urology, 2016, 195, .	0.4	0
110	Gastric cancer. Lancet, The, 2016, 388, 2654-2664.	13.7	1,560
111	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.8	16
112	International consensus guidelines on Clinical Target Volume delineation in rectal cancer. Radiotherapy and Oncology, 2016, 120, 195-201.	0.6	141
113	Survival among clinical stage III rectal cancer patients treated with different preoperative treatments: A population-based comparison. Cancer Epidemiology, 2016, 43, 35-41.	1.9	3
114	Do refined consensus guidelines improve the uniformity of clinical target volume delineation for rectal cancer? Results of a national review project. Radiotherapy and Oncology, 2016, 120, 202-206.	0.6	8
115	FDG and Beyond. Recent Results in Cancer Research, 2016, 198, 163-173.	1.8	6
116	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	2.8	73
117	Can clinical factors be used as a selection tool for an organ-preserving strategy in rectal cancer?. Acta Oncologica, 2016, 55, 1047-1052.	1.8	17
118	Hypofractionated palliative radiotherapy for bladder cancer. Supportive Care in Cancer, 2016, 24, 181-186.	2.2	25
119	Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. Acta Oncologica, 2016, 55, 486-495.	1.8	22
120	Which Patients With Rectal Cancer Do Not Need Radiotherapy?. Seminars in Radiation Oncology, 2016, 26, 199-204.	2.2	9
121	Magnetic resonance imaging for prostate cancer radiotherapy. Physica Medica, 2016, 32, 446-451.	0.7	43
122	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	1.9	102
123	Validation of an Improved Patient-Specific Mold Design for Registration of In-vivo MRI and Histology of the Prostate. Lecture Notes in Computer Science, 2016, , 36-43.	1.3	6
124	The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo. Oncotarget, 2016, 7, 84286-84298.	1.8	38
125	Oesophageal cancer. , 2016, , 365-387.		0
126	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. Journal of Urology, 2015, 193, .	0.4	1

#	ARTICLE	IF	CITATIONS
127	In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer, 2015, 15, 946.	2.6	21
128	Targeting the Hedgehog signaling pathway in cancer: beyond Smoothed. Oncotarget, 2015, 6, 13899-13913.	1.8	148
129	Tumour Movement in Proton Therapy: Solutions and Remaining Questions: A Review. Cancers, 2015, 7, 1143-1153.	3.7	49
130	Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiotherapy and Oncology, 2015, 115, 186-190.	0.6	102
131	Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. Acta Oncologica, 2015, 54, 896-902.	1.8	24
132	Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. Targeted Oncology, 2015, 10, 375-383.	3.6	17
133	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Critical Reviews in Oncology/Hematology, 2015, 95, 133-143.	4.4	23
134	Implementation of volumetric modulated arc therapy for rectal cancer: Pitfalls and challenges. Acta Oncologica, 2015, 54, 1677-1681.	1.8	8
135	Online adaptation and verification of VMAT. Medical Physics, 2015, 42, 3877-3891.	3.0	13
136	Clinical Target Volume Delineation for Rectal Cancer Radiation Therapy: Time for Updated Guidelines?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 690-691.	0.8	15
137	Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e23-109.e31.	1.6	63
138	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, Tj ETQq0 0 0 2gBT /Overlook 10 Tf	2.8	10
139	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE, 2015, 10, e0130651.	2.5	30
140	The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. Annals of Oncology, 2014, 25, ii1-ii4.	1.2	3
141	Dosimetric adaptive IMRT driven by fiducial points. Medical Physics, 2014, 41, 061716.	3.0	12
142	The role of diffusion-weighted MRI and 18F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review. Radiotherapy and Oncology, 2014, 113, 158-165.	0.6	155
143	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review. Radiotherapy and Oncology, 2014, 110, 45-54.	0.6	20
144	Does a central review platform improve the quality of radiotherapy for rectal cancer? Results of a national quality assurance project. Radiotherapy and Oncology, 2014, 111, 400-405.	0.6	20

#	ARTICLE	IF	CITATIONS
145	Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. <i>Radiotherapy and Oncology</i> , 2014, 110, 3-8.	0.6	132
146	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist's expert review. <i>Radiotherapy and Oncology</i> , 2014, 110, 195-198.	0.6	61
147	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	2.8	349
148	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , 2014, 50, 2983-2993.	2.8	56
149	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 709-713.	0.8	99
150	Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1141-57.	6.4	25
151	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1849-1861.	2.5	31
152	What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?. <i>Cancer Treatment Reviews</i> , 2014, 40, 60-67.	7.7	52
153	MP42-20 MAPPING OF PELVIC LYMPH NODES AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION INCLUDING PRE-SACRAL AND COMMON ILIAC REGIONS. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
154	The Value of Magnetic Resonance Imaging for Radiotherapy Planning. <i>Seminars in Radiation Oncology</i> , 2014, 24, 151-159.	2.2	113
155	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	1.9	121
156	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3501-3501.	1.6	51
157	Upper gastrointestinal cancers: Are all carcinomas truly carcinomas?. <i>Journal of Clinical Oncology</i> , 2014, 32, 20-20.	1.6	0
158	Methylation-guided stratification of patients with high-risk prostate cancer for the prediction of clinical failure.. <i>Journal of Clinical Oncology</i> , 2014, 32, 155-155.	1.6	0
159	Investigation of possible endogenous hypoxia markers in colorectal cancer. <i>International Journal of Radiation Biology</i> , 2013, 89, 9-15.	1.8	12
160	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 960-967.	0.8	16
161	Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. <i>European Urology</i> , 2013, 63, 450-458.	1.9	216
162	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	2.8	76

#	ARTICLE	IF	CITATIONS
163	Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 1336-1344.	1.8	12
164	18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study. <i>EJNMMI Research</i> , 2013, 3, 59.	2.5	2
165	CT- and MRI-based seed localization in postimplant evaluation after prostate brachytherapy. <i>Brachytherapy</i> , 2013, 12, 580-588.	0.5	19
166	Patient Positioning Based on a Radioactive Tracer Implanted in Patients With Localized Prostate Cancer: A Performance and Safety Evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 555-560.	0.8	7
167	Significant impact of transient deterioration of renal function on dosimetry in PRRT. <i>Annals of Nuclear Medicine</i> , 2013, 27, 74-77.	2.2	9
168	Influence of Time Delay on the Estimated Lung Shunt Fraction on 99mTc-Labeled MAA Scintigraphy for 90Y Microsphere Treatment Planning. <i>Clinical Nuclear Medicine</i> , 2013, 38, 940-942.	1.3	25
169	How do patients between the age of 65 and 75 use a web-based decision aid for treatment choice in localized prostate cancer?. <i>Journal of Evidence-Based Medicine</i> , 2013, 6, 167-172.	2.4	7
170	Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 1392-1401.	3.4	150
171	Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13979-14007.	4.1	95
172	The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e151-e154.	3.8	1
173	The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e151-e154.	3.8	1
174	Dose prescription and treatment planning based on FMISO-PET hypoxia. <i>Acta Oncol</i> ³ <i>gica</i> , 2012, 51, 222-230.	1.8	85
175	Exploring Limits for Data Registration in the Context of PROCARE, a Quality Improvement Project on Rectal Cancer. <i>Acta Chirurgica Belgica</i> , 2012, 112, 15-23.	0.4	4
176	What Is the Role of IMRT and IGRT in Rectal Cancer?. , 2012, , 129-148.		0
177	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet, The</i> , 2012, 380, 2018-2027.	13.7	759
178	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. <i>European Urology</i> , 2012, 62, 472-487.	1.9	157
179	Value of Diffusion-Weighted Magnetic Resonance Imaging for Prediction and Early Assessment of Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: Preliminary Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 863-870.	0.8	178
180	The Benefits of Including Clinical Factors in Rectal Normal Tissue Complication Probability Modeling After Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1233-1242.	0.8	68

#	ARTICLE	IF	CITATIONS
181	Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1486-1492.	0.8	44
182	Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 901-908.	0.8	114
183	Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiotherapy and Oncology, 2012, 104, 192-198.	0.6	61
184	Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. European Journal of Radiology, 2012, 81, e217-e222.	2.6	55
185	Impact of Interval between Neoadjuvant Chemoradiotherapy and TME for Locally Advanced Rectal Cancer on Pathologic Response and Oncologic Outcome. Annals of Surgical Oncology, 2012, 19, 2833-2841.	1.5	130
186	EORTC Radiation Oncology Group: 50 years of continuous accomplishments. European Journal of Cancer, Supplement, 2012, 10, 150-159.	2.2	3
187	Nodal Staging in Prostate Cancer: Still an Unresolved Issue. European Urology, 2012, 61, 1139-1141.	1.9	2
188	EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. Clinical Cancer Research, 2011, 17, 5161-5169.	7.0	42
189	Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiotherapy and Oncology, 2011, 98, 126-133.	0.6	89
190	Intrafractional prostate motion during online image guided intensity-modulated radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 98, 181-186.	0.6	42
191	The ESTRO Breur Lecture 2010: Toward a tailored patient approach in rectal cancer. Radiotherapy and Oncology, 2011, 100, 15-21.	0.6	20
192	Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 255.	1.6	156
193	Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases. European Urology, 2011, 60, 125-130.	1.9	142
194	Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation. Annals of Surgical Oncology, 2011, 18, 684-690.	1.5	21
195	Diffusion-Weighted MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer: A Multicenter Study. Annals of Surgical Oncology, 2011, 18, 2224-2231.	1.5	335
196	Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. Clinical Cancer Research, 2011, 17, 3469-3477.	7.0	51
197	Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy. Journal of Clinical Oncology, 2011, 29, e579-e581.	1.6	8
198	Fast, accurate, and robust automatic marker detection for motion correction based on oblique kV or MV projection image pairs. Medical Physics, 2010, 37, 1554-1564.	3.0	22

#	ARTICLE	IF	CITATIONS
199	How Might Knowledge of the Molecular Biology of Rectal Cancer Aid Us in Deciding Treatment?. Current Colorectal Cancer Reports, 2010, 6, 221-227.	0.5	1
200	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
201	Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation. Clinical Cancer Research, 2010, 16, 2709-2714.	7.0	29
202	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. Journal of Clinical Oncology, 2010, 28, 4450-4456.	1.6	254
203	External Beam Radiotherapy for Prostate Cancer. Journal of Endourology, 2010, 24, 781-789.	2.1	10
204	The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncologica, 2010, 49, 956-963.	1.8	126
205	IMRT-based optimization approaches for volumetric modulated single arc radiotherapy planning. Radiotherapy and Oncology, 2010, 95, 149-152.	0.6	21
206	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII. Radiotherapy and Oncology, 2010, 97, 36-39.	0.6	23
207	A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiotherapy and Oncology, 2010, 97, 474-479.	0.6	37
208	Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology, 2010, 96, 339-346.	0.6	50
209	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2010, 11, 835-844.	10.7	1,532
210	A practice survey of the evolution of rectal cancer management. Bulletin Du Cancer, 2009, 96, E45-E51.	1.6	1
211	Clinical Response of Renal Cell Carcinoma to Dexamethasone. Cancer Investigation, 2009, 27, 529-532.	1.3	1
212	Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer. Journal of Clinical Oncology, 2009, 27, 2751-2757.	1.6	94
213	Validation of nonrigid registration for multi-tracer PET-CT treatment planning in rectal cancer radiotherapy. , 2009, , .		0
214	18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. International Journal of Radiation Biology, 2009, 85, 763-771.	1.8	10
215	Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. International Journal of Colorectal Disease, 2009, 24, 129-138.	2.2	29
216	[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 209-218.	6.4	47

#	ARTICLE	IF	CITATIONS
217	Biological Image-Guided Radiotherapy in Rectal Cancer: Challenges and Pitfalls. International Journal of Radiation Oncology Biology Physics, 2009, 75, 782-790.	0.8	47
218	A kernel-based integration of genome-wide data for clinical decision support. Genome Medicine, 2009, 1, 39.	8.2	61
219	A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer. Radiotherapy and Oncology, 2009, 90, 331-336.	0.6	13
220	EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiotherapy and Oncology, 2009, 92, 164-175.	0.6	130
221	Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancer. Radiotherapy and Oncology, 2009, 93, 273-278.	0.6	38
222	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.6	275
223	A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. Radiation Oncology, 2008, 3, 30.	2.7	6
224	Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy. European Journal of Cancer, 2008, 44, 791-797.	2.8	22
225	Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. Radiotherapy and Oncology, 2008, 89, 353-360.	0.6	24
226	IGRT in rectal cancer. Acta Oncol ³ gica, 2008, 47, 1317-1324.	1.8	46
227	T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy. Clinical Cancer Research, 2008, 14, 4883-4890.	7.0	135
228	Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. Acta Oncol ³ gica, 2008, 47, 1237-1248.	1.8	76
229	PRINCIPLES OF RADIOTHERAPY. , 2008, , 502-508.		0
230	Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2008, , 166-77.	0.7	14
231	Set-up verification on a belly-board device using electronic portal imaging. Journal of Radiotherapy in Practice, 2007, 6, 73-82.	0.5	4
232	Radiotherapy for Bladder Cancer. Urology, 2007, 69, 80-92.	1.0	68
233	Surgery alone for advanced prostate cancer?. European Journal of Cancer, Supplement, 2007, 5, 157-169.	2.2	1
234	In Regards to Bujko etÂal. (Int J Radiat Oncol Biol Phys 2007;68:313â€“316). International Journal of Radiation Oncology Biology Physics, 2007, 69, 639-640.	0.8	3

#	ARTICLE	IF	CITATIONS
235	Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiation Oncology, 2007, 2, 29.	2.7	38
236	A Pretreatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer. European Urology, 2007, 51, 388-396.	1.9	54
237	Adaptive RT in Rectal Cancer: Superior to 3D-CRT? A Simple Question, a Complex Answer. Strahlentherapie Und Onkologie, 2007, 183, 21-23.	2.0	10
238	Perineal Colostomy with Appendicostomy as an Alternative for an Abdominal Colostomy: Symptoms, Functional Status, Quality of Life, and Perceived Health. Diseases of the Colon and Rectum, 2007, 50, 817-824.	1.3	19
239	Een beslissingshulp voor patiënten met gelokaliseerde prostaatkanker: eerste resultaten. Tijdschrift Voor Geneeskunde, 2007, 63, 15-21.	0.0	6
240	PET-based treatment planning in radiotherapy: a new standard?. Journal of Nuclear Medicine, 2007, 48 Suppl 1, 68S-77S.	5.0	62
241	The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiotherapy and Oncology, 2006, 79, 1-14.	0.6	32
242	Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom. Radiotherapy and Oncology, 2006, 79, 190-197.	0.6	32
243	Molecular responses of rectal cancer to preoperative chemoradiation. Radiotherapy and Oncology, 2006, 80, 172-177.	0.6	37
244	Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. Radiotherapy and Oncology, 2006, 80, 143-150.	0.6	9
245	Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas. Annals of Surgery, 2006, 243, 334-340.	4.2	98
246	In regard to Ciernik et al.: Automated Functional Image-Guided Radiation Treatment Planning for Rectal Cancer (Int J Radiat Oncol Biol Phys 2005;62:893-900). International Journal of Radiation Oncology Biology Physics, 2006, 64, 1611-1612.	0.8	3
247	Definition and delineation of the clinical target volume for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1129-1142.	0.8	203
248	Nonrigid Registration of Multitemporal CT and MR Images for Radiotherapy Treatment Planning. Lecture Notes in Computer Science, 2006, , 297-305.	1.3	4
249	Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial) Tj ETQq1 1 0.784314 rgBT /Overlock 13.7 1,096	13.7	1,096
250	Where next with preoperative radiation therapy for rectal cancer?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 597-602.	0.8	40
251	Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiotherapy and Oncology, 2004, 73, 269-275.	0.6	121
252	Adjuvant therapy for pancreatic cancer: current status and future directions. Oncologia, 2004, 27, .	0.0	0

#	ARTICLE	IF	CITATIONS
253	The biological basis of fractionation. Rays, 2004, 29, 231-6.	0.2	11
254	Upregulated expression of VEGF and Ca IX correlate with the vascular metastasis pattern of intestinal type carcinoma. Gastroenterology, 2003, 124, A184.	1.3	1
255	Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiotherapy and Oncology, 2003, 68, 69-74.	0.6	183
256	Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. Radiotherapy and Oncology, 2002, 65, 105-108.	0.6	19
257	An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Annals of Surgical Oncology, 2002, 9, 292-297.	1.5	6
258	Is there a future for cell kinetic measurements using IdUrd or BdUrd?. International Journal of Radiation Oncology Biology Physics, 2001, 49, 505-511.	0.8	11
259	Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiotherapy and Oncology, 2000, 55, 325-333.	0.6	25
260	Title is missing!. Annals of Oncology, 2000, 11, 165-172.	1.2	3
261	The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. , 1999, 85, 803-811.		44
262	The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiotherapy and Oncology, 1999, 50, 13-23.	0.6	139
263	Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: is it worthwhile to measure Tpot?. Radiotherapy and Oncology, 1998, 46, 157-167.	0.6	35
264	Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy and Oncology, 1998, 47, 149-153.	0.6	75
265	Microscopic Vascular Invasion is the Most Relevant Prognosticator After Radical Nephrectomy for Clinically Nonmetastatic Renal Cell Carcinoma. Journal of Urology, 1997, 158, 45-49.	0.4	137
266	Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?. Radiotherapy and Oncology, 1997, 45, 39-47.	0.6	20
267	Non-invasive tumour perfusion measurement by dynamic CT: preliminary results. Radiotherapy and Oncology, 1997, 44, 159-162.	0.6	48
268	Mucin-Secreting Adenocarcinoma of the Prostate with Neuroendocrine Differentiation and Paneth-Like Cells. American Journal of Surgical Pathology, 1994, 18, 200-207.	3.7	17